These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

137 related articles for article (PubMed ID: 20095429)

  • 21. Acellular vaccines induce cell-mediated immunity to Bordetella pertussis antigens in infants undergoing primary vaccination against pertussis.
    Ausiello CM; Urbani F; La Sala A; Lande R; Piscitelli A; Cassone A
    Dev Biol Stand; 1997; 89():315-20. PubMed ID: 9272365
    [TBL] [Abstract][Full Text] [Related]  

  • 22. A genetically inactivated two-component acellular pertussis vaccine, alone or combined with tetanus and reduced-dose diphtheria vaccines, in adolescents: a phase 2/3, randomised controlled non-inferiority trial.
    Sricharoenchai S; Sirivichayakul C; Chokephaibulkit K; Pitisuttithum P; Dhitavat J; Pitisuthitham A; Phongsamart W; Boonnak K; Lapphra K; Sabmee Y; Wittawatmongkol O; Chinwangso P; Poredi IK; Petre J; Thai PH; Viviani S
    Lancet Infect Dis; 2018 Jan; 18(1):58-67. PubMed ID: 29066131
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Effect of priming with diphtheria and tetanus toxoids combined with whole-cell pertussis vaccine or with acellular pertussis vaccine on the safety and immunogenicity of a booster dose of an acellular pertussis vaccine containing a genetically inactivated pertussis toxin in fifteen- to twenty-one-month-old children. Italian Multicenter Group for the Study of Recombinant Acellular Pertussis Vaccine.
    Podda A; Bona G; Canciani G; Pistilli AM; Contu B; Furlan R; Meloni T; Stramare D; Titone L; Rappuoli R
    J Pediatr; 1995 Aug; 127(2):238-43. PubMed ID: 7636648
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Cell-mediated immunity and antibody responses to Bordetella pertussis antigens in children with a history of pertussis infection and in recipients of an acellular pertussis vaccine.
    Ausiello CM; Lande R; Urbani F; Di Carlo B; Stefanelli P; Salmaso S; Mastrantonio P; Cassone A
    J Infect Dis; 2000 Jun; 181(6):1989-95. PubMed ID: 10837180
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Laboratory investigation of immune responses to acellular pertussis vaccines when used for boosting adolescents after primary immunisation with whole cell pertussis vaccines: a comparison with data from clinical study.
    Reynolds E; Walker B; Xing D; Southern J; Asokanathan C; Dagg B; Corbel M; Miller E
    Vaccine; 2006 Apr; 24(16):3248-57. PubMed ID: 16480794
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Comparison of a fifth dose of a five-component acellular or a whole cell pertussis vaccine in children four to six years of age.
    Halperin SA; Scheifele D; Barreto L; Pim C; Guasparini R; Medd L; Meekison W; Eastwood BJ
    Pediatr Infect Dis J; 1999 Sep; 18(9):772-9. PubMed ID: 10493336
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Acellular vaccines containing reduced quantities of pertussis antigens as a booster in adolescents.
    Tran Minh NN; He Q; Ramalho A; Kaufhold A; Viljanen MK; Arvilommi H; Mertsola J
    Pediatrics; 1999 Dec; 104(6):e70. PubMed ID: 10586004
    [TBL] [Abstract][Full Text] [Related]  

  • 28. An open-label, randomized, multicenter study of the safety, tolerability, and immunogenicity of quadrivalent human papillomavirus (types 6/11/16/18) vaccine given concomitantly with diphtheria, tetanus, pertussis, and poliomyelitis vaccine in healthy adolescents 11 to 17 years of age.
    Vesikari T; Van Damme P; Lindblad N; Pfletschinger U; Radley D; Ryan D; Vuocolo S; Haupt RM; Guris D
    Pediatr Infect Dis J; 2010 Apr; 29(4):314-8. PubMed ID: 19952980
    [TBL] [Abstract][Full Text] [Related]  

  • 29. [Acellular pertussis vaccine].
    Wiedermann G; Ambrosch F; Vanura H
    Wien Med Wochenschr; 1991; 141(12):270-2. PubMed ID: 1949820
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Serologic response and antibody-titer decay in adults with pertussis.
    Heininger U; Cherry JD; Stehr K
    Clin Infect Dis; 2004 Feb; 38(4):591-4. PubMed ID: 14765356
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Safety and immunogenicity of two acellular pertussis vaccines with different pertussis toxoid and filamentous hemagglutinin content in infants 2-6 months old.
    Halperin SA; Eastwood B; Barreto L; Mills E; Blatter M; Reisinger K; Bader G; Keyserling H; Roberts EA; Guasparini R
    Scand J Infect Dis; 1995; 27(3):279-87. PubMed ID: 8539554
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Two consecutive randomized controlled pertussis booster trials in children initially vaccinated in infancy with an acellular vaccine: The first with a five-component Tdap vaccine to 5-year olds and the second with five- or monocomponent Tdap vaccines at age 14-15 years.
    Carlsson RM; Gustafsson L; Hallander HO; Ljungman M; Olin P; Gothefors L; Nilsson L; Netterlid E
    Vaccine; 2015 Jul; 33(31):3717-25. PubMed ID: 26057135
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Type-specific efficacy of acellular pertussis vaccine.
    Aoyama T; Murase Y; Gonda T; Iwata T
    Am J Dis Child; 1988 Jan; 142(1):40-2. PubMed ID: 2893537
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Safety and immunogenicity of a combined Tetanus, Diphtheria, recombinant acellular Pertussis vaccine (TdaP) in healthy Thai adults.
    Sirivichayakul C; Chanthavanich P; Limkittikul K; Siegrist CA; Wijagkanalan W; Chinwangso P; Petre J; Hong Thai P; Chauhan M; Viviani S
    Hum Vaccin Immunother; 2017 Jan; 13(1):136-143. PubMed ID: 27686283
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Acellular pertussis vaccine for adolescents.
    de Carvalho AP; Pereira EM
    J Pediatr (Rio J); 2006 Jul; 82(3 Suppl):S15-24. PubMed ID: 16786100
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Serum IgG antibody responses to pertussis toxin and filamentous hemagglutinin in nonvaccinated and vaccinated children and adults with pertussis.
    Trollfors B; Taranger J; Lagergård T; Sundh V; Bryla DA; Schneerson R; Robbins JB
    Clin Infect Dis; 1999 Mar; 28(3):552-9. PubMed ID: 10194077
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Serological correlates of immunity to Bordetella pertussis.
    Hewlett EL; Halperin SA
    Vaccine; 1998 Dec; 16(20):1899-900. PubMed ID: 9796040
    [No Abstract]   [Full Text] [Related]  

  • 38. Immunogenicity and Safety of Monovalent Acellular Pertussis Vaccine at Birth: A Randomized Clinical Trial.
    Wood N; Nolan T; Marshall H; Richmond P; Gibbs E; Perrett K; McIntyre P
    JAMA Pediatr; 2018 Nov; 172(11):1045-1052. PubMed ID: 30208475
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Antibody responses after vaccination and disease against leukocytosis promoting factor, filamentous hemagglutinin, lipopolysaccharide and a protein binding to complement-fixing antibodies induced during whooping cough.
    Winsnes R; Lønnes T; Møgster B; Berdal BP
    Dev Biol Stand; 1985; 61():353-65. PubMed ID: 2872124
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Acellular pertussis vaccine booster combined with diphtheria and tetanus toxoids for adolescents.
    Pichichero ME; Blatter MM; Kennedy WA; Hedrick J; Descamps D; Friedland LR
    Pediatrics; 2006 Apr; 117(4):1084-93. PubMed ID: 16585302
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.